Last updated: 11/19/2019 16:00:13
A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients
Trial description: A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
1992-25-11
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Reimherr, FW, Cunningham LA, Batey SH, Johnston JA, Ascher JA. A Multicenter Evaluation of the Efficacy and Safety of 150 and 300mg/d Sustained-Release Bupropion Tablets Versus Placebo in Depressed Outpatients. Clinical Therapeutics 1998; 12 (3):505-516.
Medical condition
Depressive Disorder, Major
Product
bupropion
Collaborators
Not applicable
Study date(s)
November 1991 to November 1992
Type
Interventional
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
1992-25-11
Actual study completion date
1992-25-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website